

ATCIP 2025

Antimicrobial Therapy in
Immunocompromised
and Critically Ill Patients:
Management and
Perspectives

8-9 May 2025

Villa Sassa Hotel, Via Tesserete 10, Lugano

www.atcip.org



UPDATE ON THE THERAPY OF IMMUNOCOMPROMISED AND CRITICALLY ILL PATIENTS

Critically ill patients are at increased risk of developing severe and often fatal infections and infectious complications. A large investment of financial and medical resources has improved outcomes, but the optimal treatment options for these patients are still matter of discussions among the experts.

Infections, sepsis, and septic shock are leading causes of morbidity and mortality in the intensive care unit (ICU), and physicians dedicate many resources to their prevention, diagnosis, and therapy, as well as to the evaluation of the treatment outcomes. Improvement in the management of infections in critically ill patients at high risk for complications, and decrease of adverse outcomes, will most likely be the results of better quality of care, the development of new models to evaluate outcomes data, questioning and revising currently accepted standards of care, the implementation of new ideas and the performance of innovative clinical trials, and a paradigm shift in the treatment procedures, considering that the slow pace observed in the development of new, effective antibiotics cannot be the driving force of progress. The fast advances in the development of mathematical models evaluating infectious processes, including genetics as well as statistical and artificial intelligence modelling, are also key to a reliable evaluation of causes and therapeutic approaches, ultimately improving outcomes of infectious disease.

With a focus on practical aspects, the seventh congress on Antimicrobial Therapy in Immunocompromised and Critically Ill Patients (ATCIP) will review the latest advances in the epidemiology, diagnosis, and therapy of infections in immunocompromised and critically ill patients. Experts will provide an updated insight in the research and therapy of infectious diseases during plenary sessions and an interactive session. Advances in clinical mycology, as well as the progress in the epidemiology, diagnosis, and therapy of infectious concomitant diseases in solid organ transplanted (SOT) patients will be discussed. A session will be dedicated to the use of vaccines in immunocompromised patients and the infectious complications of cellular treatments in oncology. Experts will also discuss the use of new antivirals and other therapies in Hepatitis B and D as well as the use of ART in HIV. Infectious disease in the ICU will also have a prominent role, with talks reviewing the importance of sinks, the opportunities and obstacles associated with the use of AI, and the implementation of the new FUNGINOS aspergillosis guidelines in the ICU. The programme will be completed with satellite symposia discussing recent advances in the development of new drugs and treatment options. Overall, the congress promises to become not only an exciting opportunity to learn from internationally known experts, but also to be an important networking platform that will allow clinical practitioners to interact with leading researchers in the infectious diseases field.

WELCOME TO LUGANO

Lugano is a small town located in Southern Switzerland. It can be easily and rapidly reached by train or bus from the Malpensa airport. The congress venue is the Villa Sassa Hotel, conveniently located at walking distance from the Lugano Main Station and downtown.

OBJECTIVES

At the end of the congress, the participants should be able to approach the most common issues and controversies related to difficult-to-treat infectious diseases in immunocompromised and critically ill patients and have gathered not only theoretical but also real-life experience to be translated into daily clinical practice.

WHO SHOULD ATTEND

Infectious disease and intensive care specialists, oncologists and haemato-oncologists, transplant specialists, clinical microbiologists, as well as other health professionals involved in the care of critically ill and immunocompromised patients.

SCIENTIFIC COMMITTEE

ENOS BERNASCONI, MD, Lugano, Switzerland

LUIGIA ELZI, MD, Bellinzona, Switzerland

CHRISTIAN GARZONI, MD, Lugano, Switzerland

PAOLO GROSSI, MD, Varese, Italy

OSCAR MARCHETTI, MD, Morges and Lausanne, Switzerland

MATTEO MOMBELLI, MD, Locarno, Switzerland

LINDA MÜLLER, PhD, Bellinzona, Switzerland

ORLANDO PETRINI, PhD, Lugano, Switzerland

WED 7 MAY 2025
(afternoon)

ADMINISTRATIVE SESSIONS
closed meetings for members only

16.00-18.00 **General Assemblies**
STCS Infectious Diseases
Funginos

THU 8 MAY 2025

09.20 **WELCOME, INTRODUCTION**
GIORGIO MERLANI, *Bellinzona, Switzerland*

FUNGINOS SYMPOSIUM: FUNGAL INFECTIONS
Chairs: OSCAR MARCHETTI, DIONYSIOS NEOFYTOS

09.30 Introduction

09.40 *Candida auris*
FRÉDÉRIC LAMOTH, *Lausanne, Switzerland*

10.00 Invasive aspergillosis in lung transplant patient
LAURA N. WALT, *Bern, Switzerland*

10.20 Molecular diagnostics
LAURENCE MILLON, *Besançon, France*

10.40 UTI infections by non-albicans
Candida species
NINA KHANNA, *Basel, Switzerland*

11.00 Q&A - Discussion

11.20 **Sponsored Symposium 1**

12.20 **LUNCH**

STCS SYMPOSIUM
Chairs: CHRISTIAN GARZONI, PAOLO GROSSI

13.00 CAR-T cells to treat infectious diseases
PATRIZIA COMOLI, *Pavia, Italy*

13.20 CMV prevention in SOT patients
CÉDRIC HIRZEL, *Basel, Switzerland*

13.40 SOT in HBV, HCV, HDV, and HEV
infected patients
PATRIZIA BURRA, *Padua, Italy (virtual)*

14.00 Metagenomics of infectious diseases
CLAIRE BERTELLI, *Lausanne, Switzerland*

14.20 Q&A - Discussion

SESSION III: ONCOLOGY
Chairs: BERNARD GERBER, LUIGIA ELZI

14.35 Vaccines' choice for the immunocompromised
traveller. Challenges in the approach to the
immunocompromised traveller
GILLES ÉPERON, *Geneva, Switzerland*

14:55 Infectious complications of cellular
treatments in oncology
ERIKA KAMPOURI, *Lausanne, Switzerland*

15.15 Neutropenic enterocolitis: fresh blood
on an old concept
PIERRE-YVES BOCHUD, *Lausanne, Switzerland*

15.35 Q&A - Discussion

15.50 **☕ COFFEE BREAK**

16.10 **Sponsored Symposium 2**

17.05 Q&A - Discussion

**SESSION IV: NEW ANTIVIRALS AND THERAPIES FOR
HBV, HDV, AND HIV**

Chairs: ENOS BERNASCONI, PAOLO GROSSI

17.15 HBV/HDV
PIETRO LAMPERTICO, *Milan, Italy (virtual)*

17.35 Modern ART
ALEXANDRA CALMY, *Geneva, Switzerland*

17.55 Q&A - Discussion

FRI 9 MAY 2025

SESSION V: ICU

Chairs: PAOLO MERLANI, ENOS BERNASCONI

08.30 Are sinks in the ICU a thing of the past?
GAUD CATHO, Geneva & Sion, Switzerland

08.50 Situation Awareness in the ICU:
Visual Patient Avatar
DAVID TSCHOLL, Zurich, Switzerland

09.10 New FUNGINOS guidelines on invasive
aspergillosis in the ICU
Epidemiology
WERNER ALBRICH, St Gallen, Switzerland
Definitions
DYONISIOS NEOFYTOS, Geneva, Switzerland
Diagnosis
FRÉDÉRIC LAMOTH, Lausanne, Switzerland
Management
NINA KHANNA, Basel, Switzerland

09.55 Q&A - Discussion

10.10 ☕ COFFEE BREAK

10.30

Sponsored Symposium 3

11.05

Sponsored Symposium 4

11.50 🍴 LUNCH

HOT TOPICS IN EMERGING DISEASES

Chairs: GIORGIO MERLANI, ORLANDO PETRINI

13.00 Introduction
GIORGIO MERLANI, Bellinzona, Switzerland

13.05 H5N1 avian flu: where do we stand?
PAULINE VETTER, Geneva, Switzerland

13.45 Q&A - Discussion

SESSION VI: INTERACTIVE CASES

Chairs: MATTEO MOMBELLI, LINDA MÜLLER

14.00 Interactive Cases

16.30 CLOSING REMARKS

DAY 1 | 8 MAY 2025 | 11.20-12.20

1 ViiV SPONSORED SYMPOSIUM



**IGNITING PROGRESS: EXPLORING 2DR
THERAPIES AND EMPOWERING PATIENT
SHARED DECISION MAKING IN HIV CARE**
Chair: **MATTHIAS CAVASSINI**
Speakers: *MARCO BONGIOVANNI,
LOIC LHOPITALIER*

DAY 1 | 8 MAY 2025 | 16.10-17.10

2 Pfizer SPONSORED SYMPOSIUM



16.10 Introduction
16.15 RSV Vaccines
ULRICH HEININGER, Basel, Switzerland
16.40 Infections by carbapenem-resistant
Enterobacteriaceae
DIEGO ANDREY, Geneva, Switzerland

DAY 2 | 9 MAY 2025 | 10.30-11.00

3 MSD SPONSORED SYMPOSIUM



**CMV MANAGEMENT IN SOLID ORGAN
TRANSPLANTATION - PATIENT CASES**
Chair: **DIONYSIOS NEOFYTOS, Geneva, Switzerland**

10.30 Introduction
10.35 Case report: a renal transplant patient
LENA ROYSTON, Geneva, Switzerland
10.45 Case report: a lung transplant patient
ERIKA KAMPOURI, Lausanne, Switzerland
10.55 Discussion and closing

DAY 2 | 9 MAY 2025 | 11.05-11.50

4 Gilead SPONSORED SYMPOSIUM



OPTIMIZING ANTIFUNGAL TREATMENT
Chair: **DIONYSIOS NEOFYTOS, Geneva, Switzerland**

REGISTRATION FEES

FULL CONGRESS	Before APRIL 15TH	After APRIL 15TH	Last minute On-site
Physicians, PhD, other academics	250.00 CHF	330.00 CHF	350.00 CHF
Nurses	100.00 CHF	110.00 CHF	130.00 CHF
Resident Physicians, Postdoctoral students*	100.00 CHF	110.00 CHF	130.00 CHF
Students	50.00 CHF	75.00 CHF	75.00 CHF

Fees include VAT (8.1%)

* Residents (holding an M.D. degree and practicing medicine in a hospital or clinic under the direct or indirect supervision of an attending physician) and postdoctoral students should produce a certification by their supervisors at the time of getting their congress material on site.

REGISTRATION FEE INCLUDES:

- Participation in the conference
- Access to the Exhibition Area
- Conference kit
- Lunches
- Coffee breaks
- Certificate of attendance

HOW TO ATTEND



REGISTER HERE
OR SCAN THE QR CODE

Visit www.atcip.org for further information.



CANCELLATION AND REFUNDS

Before 7 April 2025: 50% of the amount paid
After 7 April 2025: No refund

CREDITS

Foederatio Analyticorum Medicinalium
Helveticorum (FAMH)
DAY 1 | 5 credits
DAY 2 | 6 credits

UEMS-EACCME® CME:

An application for the event has been made.

MEETING VENUE

Villa Sassa Hotel
Via Tesserete 10
6900 Lugano
Switzerland



WITH THE UNCONDITIONAL SUPPORT OF:



Ente Ospedaliero Cantonale
Fondo Ricerca Malattie Infettive



ORGANIZING SECRETARY



Via Coremmo , 1 - 6900 Lugano, Switzerland
Tel. +41 (0)91 9676803 - +39 02 86882050
info@atcip.org - www.atcip.org